Accuracy of ICCMS Versus Simplified Cariogram
Launched by KIROLOS HISHAM NADI SEDEK · Jun 3, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare two different methods for assessing the risk of dental cavities, also known as caries. The researchers want to see if the ICCMs Caries risk and likelihood matrix is more accurate than the simplified Cariogram in predicting how likely someone is to develop cavities. Understanding which method is more effective can help dentists provide better care and advice to their patients.
To participate in this study, you need to be between the ages of 18 and 29 and currently have dental caries or have had dental restorations, like fillings. Unfortunately, if you don’t have any cavities or have a psychiatric condition, you won’t be eligible. If you join the trial, you’ll be asked to undergo some assessments related to your dental health. The study is not yet actively recruiting participants, but it aims to gather valuable information that could improve how we assess cavity risk in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ranging from 18 to 29 years.
- • The presence of dental caries or restoration.
- Exclusion Criteria:
- • Patients with no caries.
- • Patients diagnosed of psychiatric disease.
- • Patients not willing to be part of the study or ones who refuse to sign the informed consent.
About Kirolos Hisham Nadi Sedek
Kirolos Hisham Nadi Sedek is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on ethical practices and regulatory compliance, Kirolos aims to facilitate the development of novel therapeutics and interventions across various therapeutic areas. By fostering collaboration with healthcare professionals and research institutions, Kirolos ensures that clinical trials are conducted with the highest standards of integrity and transparency, ultimately contributing to the global body of medical knowledge and enhancing therapeutic options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported